Pfizer Inc. (NYSE:PFE) announced that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Pfizer’s vaccine candidate, bivalent rLP2086, currently under investigation for the prevention of invasive meningococcal disease due to Neisseria meningitidis serogroup B in persons 10 – 25 years of age. Disease caused by Neisseria meningitidisserogroup B has been estimated at between 20,000 and 80,000 cases per year globally, and can result in death or significant long-term disabilities, including brain damage and hearing loss.1,2. Pfizer Inc. (NYSE:PFE) shares after opening at $32.12 on last trade day and at the end of the day closed at $31.91. Company price to sales ratio in past twelve months was calculated as 4.21 and price to cash ratio as 6.71. Pfizer Inc. (NYSE:PFE) showed a positive weekly performance of 2.54%.
Bloomberg reporter Drew Armstrong has been doing some great reporting on the controversy surrounding Gilead Sciences, Inc. (NASDAQ:GILD) and it’s $1,000-a-day hepatitis C pill Sovaldi. The issues has definitely weighed some on Gilead’s stock price recently. Armstrong published a new story discussing how Medicaid providers were limiting access to Sovaldi because of its price. Gilead Sciences, Inc. (NASDAQ:GILD) shares fell -1.33% in last trading session and ended the day on $75.53. GILD return on equity ratio is recorded as 28.30% and its return on assets is 13.70%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 69.64%.
Zacks reaffirmed their neutral rating on shares of Bristol-Myers Squibb (NYSE:BMY) in a report released on Wednesday, Analyst Ratings Network.com reports. Zacks currently has a $57.00 price objective on the stock. Bristol-Myers Squibb Co (NYSE:BMY) shares moved down -1.75% in last trading session and was closed at $53.78, while trading in range of $53.50 – $54.58. Bristol-Myers Squibb Co (NYSE:BMY) year to date (YTD) performance is 0.57%.
Merck & Co. (NYSE:MRK) had its target price boosted by Jefferies Group to $57.00 in a report issued on Wednesday, Stock Ratings News reports. Merck & Co., Inc. (NYSE:MRK) weekly performance is -0.36%. On last trading day company shares ended up $55.59. Merck & Co., Inc. (NYSE:MRK) distance from 50-day simple moving average (SMA50) is 2.99%. Analysts mean target price for the company is $56.44.